Regenexx is a Research Based Stem Cell Procedure | Regenexx™

The Centeno-Schultz Clinic is a research-based medical practice founded by Christopher J. Centeno,M.D., and John R. Schultz, M.D. . The Regenexx procedures have been studied extensively for several years and we maintain what we believe to be the worlds largest human mesenchymal stem cell re-implantation database for orthopedic purposes.

The original Regenexx-C procedure was first used as part of an IRB supervised clinical trial from 2005-2007. During this time our medical practice invested hundreds of thousands of dollars in providinginvestigationalcare, with all patientsreceivingbefore and after research-grade MRIs. For more information on how physicians innovate versus how FDA/drugcompaniesdiscover new drugs, see this link. By late 2007, once the physicians were satisfied that the procedure was working and that the complications were less than existing surgical care, the clinic began treating patients. Since that time the clinic has published many medical research papers listed in the U.S. Library of Medicine (see this link for an incomplete list). Every patient treated by us is entered into a treatment registry and will be contacted atvarioustime points regarding the outcome of the procedure, any complications, etc As a result, we have extensive experience in what works and what doesnt work. In addition, based onourpublished complications papers, our procedure produces significantly fewer complications than the more invasive surgical procedures it helps many patients avoid.

In addition to peer reviewed publications, we also publish our registry data online. See data on Regenexx-SD and the Regenexx-PL-Disc procedures. Pre-publication data and before/after MRI case studies can often be found on the Regenexx blog.

Centeno CJ,D Freeman M.

Wien Med Wochenschr.2013 Aug 15.

ABSTRACT

BACKGROUND: Mesenchymal stem cells (MSCs) show promising clinical potential as multipotent therapeutic agents in regenerative medicine, including a number of orthopedic applications. Objective: To study the possible value of MSCs injected intra-articular in patients with carpometecarpal (CMC) joint and hand osteoarthritis (OA).

METHODS: This is a prospective, case series with an untreated control that was obtained through a convenience sample. Patients underwent a bone marrow aspiration with isolation and culture expansion of MSCs using a serum free, autologous platelet lysate. Autologous MSCs were injected intra-articular utilizing imaging guidance. Percentage improvement, functional and visual analog scale data was collected via survey at pre-procedure, 3 months, 6 months, and annually.

RESULTS: Six OA patients and four controls were recruited. The mean reported pain relief was significantly higher +60% in the thumb OA group (n=6, p=.032) than in the control -18.75% (n=4). The average time reporting was 11.83 +/- 5.70 months and 9.55 +/- 6.49 months for both groups, respectively. On average, a greater than 30% reduction were observed in all VAS scale metrics (n=5), average reporting time was 13 +/-5.52 months. The majority of patients (66.7%, n=6) reported an increase in both strength and range of motion, average reporting time was 11.83 +/- 5.7 months. No complications were reported.

CONCLUSIONS: Percutaneous implantation of cultured MSCs into the carpometecarpal joint was associated with patient reported improvement in pain and function that was not seen in an untreated control. In addition, all patients within this small case series reported no complications.

Go here to see the original:
Regenexx is a Research Based Stem Cell Procedure | Regenexx™